Ontogeny and Expansion of Human Natural Killer Cells: Clinical Implications

No abstract is available for this paper.

• Publication year

  2001

• Venue

  International Reviews of Immunology

• Publication date

  2001-01-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3109/08830180109054417PMID 11878513
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biology of Natural Killer Cells

  2008cited by this paper
• lnterleukin-2 Receptor y Chain Mutation Results in X-Linked Severe Combined Immunodeficiency in Humans

  2008cited by this paper
• Differences of biodistribution, pharmacokinetics, and tumor targeting between interleukins 2 and 15.

  2000cited by this paper
• Potential mechanisms of human natural killer cell expansion in vivo during low-dose IL-2 therapy.

  2000cited by this paper
• The receptor tyrosine kinase c-kit provides a critical signal for survival, expansion, and maturation of mouse natural killer cells.

  2000cited by this paper
• Cutting Edge: IL-15 Costimulates the Generalized Shwartzman Reaction and Innate Immune IFN-γ Production In Vivo1

  2000cited by this paper
• Overview of the trastuzumab (Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer. Herceptin Multinational Investigator Study Group.

  1999cited by this paper
• Differential cytokine and chemokine gene expression by human NK cells following activation with IL-18 or IL-15 in combination with IL-12: implications for the innate immune response.

  1999cited by this paper
• Preclinical and phase I and II trials of rituximab.

  1999cited by this paper
• Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells

  1999cited by this paper
• Interleukin-12: basic principles and clinical applications.

  1999cited by this paper
• Cutting edge: expression of functional CD94/NKG2A inhibitory receptors on fetal NK1.1+Ly-49- cells: a possible mechanism of tolerance during NK cell development.

  1999cited by this paper
• Differentiation of NK1.1+, Ly49+ NK cells from flt3+ multipotent marrow progenitor cells.

  1999cited by this paper
• Development and tolerance of natural killer cells.

  1999cited by this paper
• A fatal cytokine-induced systemic inflammatory response reveals a critical role for NK cells.

  1999cited by this paper
• Costimulation of human natural killer cells is required for interferon gamma production.

  1999cited by this paper
• High-dose therapy in multiple myeloma and primary amyloidosis: an overview.

  1999cited by this paper
• Regulation of immune responses through inhibitory receptors.

  1999cited by this paper
• Differential expression and function of L-selectin on CD56bright and CD56dim natural killer cell subsets.

  1998cited by this paper
• Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice.

  1998cited by this paper
• Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15.

  1998cited by this paper
• c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities.

  1998cited by this paper
• The Transcription Factor Interferon Regulatory Factor 1 (IRF-1) Is Important during the Maturation of Natural Killer 1.1+ T Cell Receptor–α/β+ (NK1+ T) Cells, Natural Killer Cells, and Intestinal Intraepithelial T Cells

  1998cited by this paper
• Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice

  1998cited by this paper
• Ultra low dose interleukin-2 therapy promotes a type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies.

  1998cited by this paper
• Participation of the CD94 receptor complex in costimulation of human natural killer cells.

  1998cited by this paper
• Biologic effects and potential clinical applications of Flt3 ligand

  1998cited by this paper
• Natural killer cells from HIV-1+ patients produce C-C chemokines and inhibit HIV-1 infection.

  1998cited by this paper
• Evaluation of natural killer cell expansion and activation in vivo with daily subcutaneous low-dose interleukin-2 plus periodic intermediate-dose pulsing

  1998cited by this paper
• NK cells differentiated from bone marrow, cord blood and peripheral blood stem cells exhibit similar phenotype and functions

  1998cited by this paper
• IL-15 receptor maintains lymphoid homeostasis by supporting lymphocyte homing and proliferation.

  1998cited by this paper
• Interleukin-2, interleukin-15, and their receptors.

  1998cited by this paper
• Requirement for IRF-1 in the microenvironment supporting development of natural killer cells

  1998cited by this paper
• Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy.

  1998cited by this paper
• X-linked SCID and other defects of cytokine pathways.

  1998cited by this paper
• Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody.

  1998cited by this paper
• The structure and function of gamma c-dependent cytokines and receptors: regulation of T lymphocyte development and homeostasis.

  1998cited by this paper
• Flt3 Ligand Promotes the Generation of a Distinct CD34+Human Natural Killer Cell Progenitor That Responds to Interleukin-15

  1998cited by this paper
• Functional dissection of the cytoplasmic subregions of the IL‐2 receptor βc chain in primary lymphocyte populations

  1998cited by this paper
• Natural killer cell differentiation: insights from knockout and transgenic mouse models and in vitro systems

  1998cited by this paper
• Stat5b Is Essential for Natural Killer Cell–mediated Proliferation and Cytolytic Activity

  1998cited by this paper
• Natural killer cells from human immunodeficiency virus (HIV)-infected individuals are an important source of CC-chemokines and suppress HIV-1 entry and replication in vitro.

  1998cited by this paper
• Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors

  1997cited by this paper
• Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.

  1997cited by this paper
• Abnormal Development of Intestinal Intraepithelial Lymphocytes and Peripheral Natural Killer Cells in Mice Lacking the IL-2 Receptor β Chain

  1997cited by this paper
• IL-15 mediates anti-tumor effects after cyclophosphamide injection of tumor-bearing mice and enhances adoptive immunotherapy: the potential role of NK cell subpopulations.

  1997cited by this paper
• A PHASE II STUDY OF DAILY SUBCUTANEOUS (SQ) LOW DOSE INTERLEUKIN-2(IL-2) IN HIV-ASSOCIATED MALIGNANCIES.: 96

  1997cited by this paper
• Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors.

  1997cited by this paper
• Fetal liver contains committed NK progenitors, but is not a site for development of CD34+ cells into T cells.

  1997cited by this paper
• Arousal and inhibition of human NK cells

  1997cited by this paper
• CD56bright natural killer cell subsets: Characterization of distinct functional responses to interleukin‐2 and the c‐kit ligand

  1997cited by this paper
• Interleukin‐15‐induced maturation of human natural killer cells from early thymic precursors: selective expression of CD94/NKG2‐A as the only HLA class I‐specific inhibitory receptor

  1997cited by this paper
• A potential role for interleukin-15 in the regulation of human natural killer cell survival.

  1997cited by this paper
• Generation of Lytic Natural Killer 1.1+, Ly-49− Cells from Multipotential Murine Bone Marrow Progenitors in a Stroma-free Culture: Definition of Cytokine Requirements and Developmental Intermediates

  1997cited by this paper
• Natural killer cells: from no receptors to too many.

  1997cited by this paper
• Stem cell factor enhances interleukin-2-mediated expansion of murine natural killer cells in vivo.

  1997cited by this paper
• Expansion and manipulation of natural killer cells in patients with metastatic cancer by low-dose continuous infusion and intermittent bolus administration of interleukin 2.

  1996cited by this paper
• Role of interleukin-2 (IL-2), IL-7, and IL-15 in natural killer cell differentiation from cord blood hematopoietic progenitor cells and from gamma c transduced severe combined immunodeficiency X1 bone marrow cells.

  1996cited by this paper
• Daily subcutaneous injection of low-dose interleukin 2 expands natural killer cells in vivo without significant toxicity.

  1996cited by this paper
• Differential effects of interleukin-15 and interleukin-2 on differentiation of bipotential T/natural killer progenitor cells

  1996cited by this paper
• IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells.

  1996cited by this paper
• Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity.

  1996cited by this paper
• Role of interleukin-15 in the development of human CD56+ natural killer cells from CD34+ hematopoietic progenitor cells.

  1996cited by this paper
• Defective Lymphoid Development in Mice Lacking Jak3

  1995cited by this paper
• Functional Characterization of the Human Interleukin-15 Receptor (cid:97) Chain and Close Linkage of IL15RA and IL2RA Genes*

  1995cited by this paper
• Developmental defects of lymphoid cells in Jak3 kinase-deficient mice.

  1995cited by this paper
• Lymphokine requirement for the generation of natural killer cells from CD34+ hematopoietic progenitor cells.

  1995cited by this paper
• Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain.

  1995cited by this paper
• Prolonged administration of low-dose interleukin-2 in human immunodeficiency virus-associated malignancy results in selective expansion of innate immune effectors without significant clinical toxicity.

  1995cited by this paper
• Studies evaluating the antitumor activity and toxicity of interleukin-15, a new T cell growth factor: comparison with interleukin-2.

  1995cited by this paper
• Functional characterization of the human interleukin-15 receptor alpha chain and close linkage of IL15RA and IL2RA genes.

  1995cited by this paper
• Defective natural immunity: an early manifestation of human immunodeficiency virus infection

  1995cited by this paper
• Identification and cloning of a novel IL‐15 binding protein that is structurally related to the alpha chain of the IL‐2 receptor.

  1995cited by this paper
• Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain.

  1995cited by this paper
• Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor

  1994cited by this paper
• Differentiation of natural killer (NK) cells from human primitive marrow progenitors in a stroma-based long-term culture system: identification of a CD34+7+ NK progenitor.

  1994cited by this paper
• The interleukin (IL) 2 receptor beta chain is shared by IL-2 and a cytokine, provisionally designated IL-T, that stimulates T-cell proliferation and the induction of lymphokine-activated killer cells.

  1994cited by this paper
• Cloning of a T cell growth factor that interacts with the beta chain of the interleukin-2 receptor.

  1994cited by this paper
• Effect of low-dose interleukin-2 on disease relapse after T-cell-depleted allogeneic bone marrow transplantation.

  1994cited by this paper
• Low-dose interleukin 2 prevents the development of Epstein-Barr virus (EBV)-associated lymphoproliferative disease in scid/scid mice reconstituted i.p. with EBV-seropositive human peripheral blood lymphocytes.

  1994cited by this paper
• The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2.

  1994cited by this paper
• Impaired interleukin 12 production in human immunodeficiency virus- infected patients

  1994cited by this paper
• Utilization of the beta and gamma chains of the IL‐2 receptor by the novel cytokine IL‐15.

  1994cited by this paper
• Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair.

  1993cited by this paper
• Soluble stem cell factor in human serum.

  1993cited by this paper
• Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.

  1993cited by this paper
• Expression of a functional c-kit receptor on a subset of natural killer cells

  1993cited by this paper
• Genesis of human oncolytic natural killer cells from primitive CD34+CD33- bone marrow progenitors.

  1993cited by this paper
• Low-dose recombinant interleukin-2 therapy: rationale and potential clinical applications.

  1993cited by this paper
• Multifactorial nature of human immunodeficiency virus disease: implications for therapy.

  1993cited by this paper
• Histopathologic subtypes of indolent lymphomas: caricatures of the mature B-cell system.

  1993cited by this paper
• The IL-2 receptor complex: its structure, function, and target genes.

  1993cited by this paper
• Emergence of NK1.1+ cells as effectors of IFN-gamma dependent immunity to Toxoplasma gondii in MHC class I-deficient mice

  1993cited by this paper
• The immunopathogenesis of human immunodeficiency virus infection.

  1993cited by this paper
• Immune responses in interleukin-2-deficient mice.

  1993cited by this paper
• The generation of human natural killer cells from CD34+/DR- primitive progenitors in long-term bone marrow culture.

  1992cited by this paper
• Production and differentiation of NK lineage cells in long-term bone marrow cultures in the absence of exogenous growth factors.

  1992cited by this paper
• CD16- CD56+ natural killer cells after bone marrow transplantation.

  1992cited by this paper
• Clinical and immunologic effects of prolonged infusion of low-dose recombinant interleukin-2 after autologous and T-cell-depleted allogeneic bone marrow transplantation.

  1992cited by this paper
• The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2 [corrected]

  1991cited by this paper

• Advances in augmenting infiltration of active natural killer cells into pediatric and adult solid tumors

  2025cites this paper
• Effector and cytolytic function of natural killer cells in anti-cancer immunity.

  2023cites this paper
• Key Activating and Inhibitory Ligands Involved in the Mobilization of Natural Killer Cells for Cancer Immunotherapies

  2021cites this paper
• Targeting Cancer Stem Cells with Natural Killer Cell Immunotherapy

  2017cites this paper
• EXPANSION OF NK CELLS AND THERAPEUTIC USES THEREOF

  2017cites this paper
• Natural killer cell reprogramming with chimeric immune receptors.

  2013cites this paper
• Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?

  2013cites this paper
• signals and induces specific killing of leukemic cells Genetic modification of primary natural killer cells overcomes inhibitory

  2013cites this paper
• Use of allogeneic NK cells for cancer immunotherapy.

  2011cites this paper
• Expansion and activation of natural killer cells for cancer immunotherapy.

  2009cites this paper
• Retroviral gene transfer into primary human natural killer cells.

  2009cites this paper
• MTS dye based colorimetric CTLL-2 cell proliferation assay for product release and stability monitoring of interleukin-15: assay qualification, standardization and statistical analysis.

  2009cites this paper
• Signalling, inflammation and arthritis: Crossed signals: the role of interleukin-15 and -18 in autoimmunity.

  2008cites this paper
• New visions for basic research and primary prevention of pediatric allergy: An iPAC summary and future trends

  2008cites this paper
• Involvement of the innate immune system in liver regeneration and injury.

  2006cites this paper
• The Therapeutic Use of Natural-Killer Cells in Hematological Malignancies

  2006cites this paper
• and platelets erythrocytes, C57BL/6 mouse. II. Activation, cytokines, the Contribution: Effects of spaceflight on immunity in Genetic Models in Applied Physiology: Selected

  2006cites this paper
• Transcriptional control of interferon gamma synthesis by natural killer cells

  2006influential citation
• Human natural killer cell development and biology.

  2006cites this paper
• Efficient gene transfer into primary human natural killer cells by retroviral transduction.

  2005cites this paper
• Efficient infection of human natural killer cells with an EBV/retroviral hybrid vector.

  2005cites this paper
• Development of Efficient Prophylactic Vaccines and Theracines for Newborns and Infants

  2005cites this paper
• Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

  2005cites this paper
• Immunosenescence: immune deficits in the elderly and therapeutic strategies to enhance immune competence

  2005cites this paper
• Characterization of Cord Blood Natural Killer Cells: Implications for Transplantation and Neonatal Infections

  2005cites this paper
• Interleukin (IL)-15 and IL-2 Reciprocally Regulate Expression of the Chemokine Receptor CX3CR1 through Selective NFAT1- and NFAT2-dependent Mechanisms*

  2004cites this paper
• Cytokine modulation of the innate immune system in the treatment of leukemia and lymphoma.

  2004cites this paper
• NK cell and DC interactions.

  2004cites this paper
• Differential Effects of Interleukin-7 and Interleukin-15 on NK Cell Anti-Human Immunodeficiency Virus Activity

  2004cites this paper
• Stem Cell Factor and Its Receptor, c-Kit

  2004cites this paper
• Contribution of in vivo and ex vivo studies to understanding the role of antigen-presenting cells and T cell subsets in immunity to cattle diseases

  2004cites this paper
• Biology and clinical impact of human natural killer cells

  2003cites this paper
• Genetic models in applied physiology: selected contribution: effects of spaceflight on immunity in the C57BL/6 mouse. II. Activation, cytokines, erythrocytes, and platelets.

  2003cites this paper
• Natural killer cell activation in mice and men: different triggers for similar weapons?

  2002cites this paper
• Natural Killer Cells and Their Role in Disease

  2002cites this paper
• The biology of human natural killer-cell subsets.

  2001cites this paper